Process for preparing orally disintegrating tablet containing cytokines
Through the granulation step of acidifying excipients and cytokines, the stability and effectiveness of oral collapse tablets are solved, and the stability and efficacy of oral collapse tablets are improved, and they are suitable for industrial-scale manufacturing.
Patent Information
- Application Number
- CN202410723682.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-05
- Filing Date
- 2024-06-05
- Publication Date
- 2024-12-06
AI Technical Summary
There are challenges in protein stability of oral interferon, which leads to unstable side effects and efficacy of oral administration. It is difficult for existing oral tablet technology to effectively maintain the activity and stability of cytokines.
The granulation step is carried out using acidification excipients, and the acidification excipient is mixed with cytokines to form acidic powders and granules, and combined with suitable granulation methods and equipment to ensure the stability and efficacy of the cytokines.
It achieves good protein stability and efficacy of cytokines such as interferon, improves the stability and uniformity of oral collapse tablets, and is suitable for industrial-scale manufacturing.
Smart Images

Figure CN119074897A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a process for manufacturing an orally disintegrating tablet (ODT), and more particularly to a process for manufacturing an orally disintegrating tablet containing cytokines. Background Art
[0002] Cytokines are small proteins (approximately 6 to 70 kDa) that are important in cellular signaling. Due to their size, cytokines cannot cross the lipid bilayer of cells and enter the cytoplasm, so they typically exert their functions by interacting with specific cytokine receptors on the surface of target cells. Cytokines have been shown to act as immunomodulators and participate in autocrine, paracrine, and endocrine signaling.
[0003] Cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors. Cytokines can be produced by a variety of cells, including immune cells such as macrophages, B lymphocytes, T lymphocytes, and mast cells, as well as endothelial cells, fibroblasts, and various stromal cells. A specific cytokine can be produced by more than one type of cell. They can act through cell surface receptors and are particularly important to the immune system; cytokines regulate the balance between humoral and cellular immune responses and regulate the maturation, growth, and responsiveness of specific cell populations. Some cytokines promote or inhibit the effects of other cytokines in complex ways. Cytokines are important in health and disease, especially in the host's immune response to infection, inflammation, trauma, sepsis, cancer, and reproduction.
[0004] Interferons (IFNs) are proteins produced by host cells in response to the presence of pathogens such as viruses, bacteria, parasites or tumor cells. Interferons can be used for communication between cells to activate the protective and defensive effects of the immune system to eliminate pathogens or tumor cells. Nine different families of human interferons have been identified, with interferon-alpha (IFN-α) being the most widely studied. The United States has approved high-dose (mega doses) of injectable IFN-α as a treatment for several cancers, hepatitis B and hepatitis C. In the field of interferon-related technology, the conventional technology is to use high doses of interferon, such as doses greater than 1 million IU; and, typically, intramuscular injection to treat symptoms systemically.
[0005] Recently, public studies have shown that oral interferon can activate dozens of immune system genes in peripheral blood and effectively fight viruses and autoimmune diseases without the side effects of high-dose injections. However, oral interferon still faces challenges in protein stability.
[0006] Oral administration can be via, for example, orodisintegrating tablets, which can disintegrate rapidly via saliva or a small amount of water. Since orodisintegrating tablets are a convenient and easy way of administration for patients, the use of orodisintegrating tablets can improve medication compliance. However, orodisintegrating tablets are a newly developed dosage form and still have some technical difficulties such as tablet properties.
[0007] Therefore, there is still a need for orally disintegrating tablets containing cytokines such as interferon and having good protein stability. Summary of the invention
[0008] The present invention provides a process for manufacturing an orally disintegrating tablet comprising a cytokine as an active pharmaceutical ingredient, comprising: acidifying an excipient; subjecting the acidified excipient to a first granulation step to obtain an acidic powder; and mixing the acidic powder with the cytokine to a second granulation step to obtain particles comprising the cytokine.
[0009] The present invention also provides a process for manufacturing an orally disintegrating tablet comprising a cytokine as an active pharmaceutical ingredient, comprising: acidifying a first excipient; subjecting the acidified first excipient to a first granulation step to obtain a first acidic powder; sieving and granulating the first acidic powder to obtain a second acidic powder; and mixing the second acidic powder with the cytokine to perform a second granulation step to obtain first particles comprising the cytokine. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 Shown is a process for manufacturing an orally disintegrating tablet comprising cytokines as active pharmaceutical ingredients according to one embodiment of the present invention.
[0011] Figure 2 Show the protective effect of different factors on IFN-α.
[0012] Figure 3 The results of the test on the effect of the excipient acidification step of the process of the present invention are shown, wherein the IFN-α content was measured by ELISA at OD450 absorbance, with five samples per group, labeled as acidified (S1-S5) and non-acidified (S1-S5).
[0013] Figure 4 IFN-α potency test results for the first acidic powder processing step are shown.
[0014] Figure 5 Results of IFN-α potency testing showing the equipment used in the second granulation step.
[0015] Figure 6 Shows the results of the test on the effect of tablet thickness on IFN-α efficacy. DETAILED DESCRIPTION
[0016] The present invention provides a process for manufacturing an orally disintegrating tablet comprising cytokines as active pharmaceutical ingredients.
[0017] The cytokine is selected from one or more of the following groups: chemokine, interferon, interleukin, lymphokine, and tumor necrosis factor. The cytokine can be a natural cytokine, a recombinant cytokine, or a mixture thereof. The dosage of the cytokine contained in the orally disintegrating tablet is not particularly limited and can be determined according to demand.
[0018] In some embodiments, the cytokine is selected from interferons, such as type I interferons, type II interferons, and type III interferons. In one embodiment, the cytokine is interferon-alpha (IFN-α), more preferably recombinant IFN-α.
[0019] In one embodiment, the orodisintegrating tablet may contain INF-α in a dose of 1-100,000 International Units (IU). In one embodiment, the orodisintegrating tablet may contain INF-α in a dose equal to or less than 1,000 micrograms. The dose may be, for example, less than 75,000 IU, less than 50,000 IU, less than 25,000 IU, less than 10,000 IU, less than 7,500 IU, less than 5,000 IU, less than 2,500 IU, less than 1,000 IU; more than 10 IU, more than 100 IU, more than 250 IU, more than 500 IU, more than 750 IU, more than 900 IU; or a value between any two of the above values.
[0020] In the present invention, the orally disintegrating tablet includes at least one excipient. The excipient is a pharmaceutically acceptable component, and known excipients can be used, as long as the excipient can have the function of an excipient in the orally disintegrating tablet and will not have an adverse effect on the cytokine. In an embodiment, the excipient may include, for example, sugar, sugar alcohol, cellulose, polysaccharide, stearic acid, magnesium stearate, calcium stearate, polyethylene glycol, sodium lauryl sulfate, glycerol, anhydrous dicalcium phosphate, magnesium aluminosilicate, and silicon oxide. Examples of sugars include lactose, maltose, dextrin, trehalose, sucrose, etc. Examples of sugar alcohols include mannitol, erythritol, isomalt, lactitol, maltitol, sorbitol, xylitol, etc. Examples of cellulose include microcrystalline cellulose, silicified microcrystalline cellulose, powdered cellulose, etc. Examples of polysaccharides include starches such as corn starch, potato starch, pregelatinized starch, etc. In some embodiments, the excipient is a sugar. In a preferred embodiment, the excipient is maltose.
[0021] The process for manufacturing an orally disintegrating tablet comprising cytokines as active pharmaceutical ingredients comprises the following steps:
[0022] Acidifying excipients;
[0023] subjecting the acidified excipient to a first granulation step to obtain an acidic powder; and,
[0024] The acidic powder is mixed with the cytokine to perform a second granulation step to obtain granules containing the cytokine.
[0025] In the present invention, the excipient is acidified before being mixed with the active pharmaceutical ingredient (i.e., the cytokine). The acidified excipient can prevent the cytokine from protein degradation during the manufacture of the orally disintegrating tablet and can maintain the stability and content of the cytokine in the final product.
[0026] In some embodiments, the acidified excipient is prepared by the following steps: mixing an acid and water to obtain an acid solution, and mixing the excipient with the acid solution. The water can be pure water, sterile water, deionized water, etc.
[0027] The acid is added to adjust the pH value of the excipient solution. In some embodiments, the acidification step can make the excipient solution have a pH value of 3 to 10, for example, a pH value of 3.5 to 8, a pH value of 4 to 7, or a pH value of 5 to 6. Inorganic acids and / or organic acids can be used as long as the composition or properties of the orally disintegrating tablet are not destroyed or changed. Examples of the acid can include, but are not limited to, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, acetic acid, citric acid, malic acid, succinic acid, fumaric acid, lactic acid, etc. In some embodiments, the acid is citric acid.
[0028] The granulation step of the present invention is not particularly limited, and a conventional granulation method can be used. Examples of granulation methods may include, but are not limited to, high-speed shear mixing granulation, fluidized bed granulation, centrifugal granulation, drum granulation, spray granulation, etc. Considering the active pharmaceutical ingredient contained in the orally disintegrating tablet, wet granulation is preferred. In some embodiments, a high-speed shear mixing granulation method is used. In some embodiments, a fluidized bed granulation method is used.
[0029] After the excipient acidification step and the first granulation step, the obtained acidic powder can be further processed. The acidic powder obtained in the first granulation step is sometimes referred to as the "first acidic powder" below. The first acidic powder can be sieved using, for example, a 100-mesh screen, thereby being divided into powder that passes through the screen (hereinafter referred to as the "screened portion of the first acidic powder" or "screened material"), and powder that remains on the screen (hereinafter referred to as the "retained portion of the first acidic powder"). The screened portion of the first acidic powder can be further mixed with an unacidified excipient and then granulated to obtain a second acidic powder.
[0030] Next, the acidic powder may be mixed with the cytokine.
[0031] The cytokine may be contained in a solution. The solution may further include a solvent and an acid. In one embodiment, the solution comprising the cytokine, the solvent and the additive has a pH value of 3 to 10, for example, a pH value of 3.5 to 8, a pH value of 4 to 7, or a pH value of 5 to 6. As long as the cytokine is not adversely affected, the solvent may be any pharmaceutically acceptable solvent. In one embodiment, the solvent may be water, such as pure water, deionized water, and / or sterile water. As long as the cytokine is not adversely affected, the acid may be an inorganic acid and / or an organic acid. Examples of the acid may include, but are not limited to, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, acetic acid, citric acid, malic acid, succinic acid, fumaric acid, lactic acid, etc. In some embodiments, the acid is hydrochloric acid (HCl).
[0032] In some embodiments, the solution may further include an excipient, which may be the same as or different from the excipient to be acidified. In some embodiments, the solution may further include an additive, which is selected from one or more of the following groups: a buffer, a disintegrant, a binder, a colorant, a lubricant, a fluidizing agent, a surfactant, a flavoring agent, an antioxidant, a preservative, a filler, or any combination thereof.
[0033] In some embodiments, the first acidic powder is mixed with the cytokine to perform a second granulation step. In some embodiments, the second acidic powder is mixed with the cytokine to perform a second granulation step.
[0034] In some preferred embodiments, the second acidic powder is mixed with the cytokine to perform a second granulation step to obtain first granules, and then the first granules are further mixed with the remaining portion of the first acidic powder to perform a third granulation step to obtain second granules, or to perform a tableting step to obtain the tablet.
[0035] In some embodiments, one or more additional excipients may be added in any appropriate step of the process. In some embodiments, additives such as buffers, disintegrants, binders, colorants, lubricants, fluidizers, surfactants, flavoring agents, antioxidants, preservatives, fillers, or any combination thereof may be added in any appropriate step of the process. The additives are not particularly limited and may be used or added according to common knowledge in the relevant technical field. In one embodiment, the additive is magnesium stearate.
[0036] In summary, in some embodiments, the present invention provides a process for manufacturing an orally disintegrating tablet comprising a cytokine, comprising the following steps: acidifying a first excipient; subjecting the acidified first excipient to a first granulation step to obtain a first acidic powder; sieving and granulating the first acidic powder to obtain a second acidic powder; and mixing the second acidic powder with the cytokine to perform a second granulation step to obtain first particles.
[0037] The present invention also provides, in some embodiments, a process for manufacturing an orally disintegrating tablet comprising a cytokine, comprising the following steps: acidifying a first excipient; subjecting the acidified first excipient to a first granulation step to obtain a first acidic powder; sieving and granulating the first acidic powder to obtain a second acidic powder; mixing the second acidic powder with the cytokine to a second granulation step to obtain first granules; and compressing the first granules to form tablets.
[0038] The present invention also provides a process for manufacturing an orally disintegrating tablet comprising a cytokine as an active pharmaceutical ingredient, comprising: acidifying a first excipient; subjecting the acidified first excipient to a first granulation step to obtain a first acidic powder; sieving and granulating the first acidic powder to obtain a second acidic powder; mixing the second acidic powder with the cytokine to a second granulation step to obtain a first granule; and, mixing the first granule with the first excipient and / or additive, and tableting to form a tablet. In particular, the remaining portion of the first acidic powder may be mixed with the first granule.
[0039] In the present invention, the process may further include a drying step, a sieving step, and a tabletting step. The drying step is performed after the first granulation step, the second granulation step, and / or the third granulation step. After the drying step, the sieving step may be selectively performed to improve the uniformity of the obtained particles. The mesh size of the sieve used in the sieving step may be determined according to demand. After all granulation steps are completed, the particles containing the cytokine may be tableted to form an orally disintegrating tablet.
[0040] In another aspect, the present invention also provides an orally disintegrating tablet manufactured by the process of the present invention. The orally disintegrating tablet can maintain good and sufficient potency and stability of the cytokines contained therein.
[0041] The orally disintegrating tablet preparation process provided by the present invention has optimized process steps and can be applied to industrial-scale production. The process of the present invention can be used to prepare orally disintegrating tablets with excellent protein stability and cytokine efficacy.
[0042] Example
[0043] Example 1
[0044] Reference Figure 1, depicts the steps of manufacturing an orally disintegrating tablet containing interferon α (INF-α). In this example, maltose is used as an excipient that is subsequently acidified.
[0045] Preparation of active stock solution:
[0046] Add HCl (to adjust pH), sodium acetate trihydrate, and sodium chloride (NaCl) to water for injection (WFI) and continue stirring for at least 10 minutes until a clear solution is obtained by visual observation. Add human serum albumin and stir for 10 minutes. Slowly add INF-α solution to the solution and continue stirring for 3 minutes. At this point, the activity bulk solution is obtained.
[0047] Preparation of acidic powder:
[0048] The maltose was ground and sieved with a mesh size of 20. The maltose powder was sieved with Comil (mesh size 0.032 inch, 032R).
[0049] Slowly add citric acid to the water for injection while stirring. Continue stirring for 10 minutes to obtain a clear acid solution.
[0050] The acid solution is mixed with the maltose powder and mixed into a high-speed mixer granulator to produce the acid powder. The acid powder is dried in a fluidized bed granulator dryer / coater. After the drying step and before the processing step, the acid powder can be optionally passed through a 30-mesh screen (vibro-sieve separator). In this way, the first acid powder can be obtained.
[0051] Processing of acid powder:
[0052] The first acidic powder was sieved with a 100-mesh screen (vibrating screen separator) to separate the sieved material (the acidic powder that passed through the screen) and the remaining portion of the first acidic powder (the acidic powder that did not pass through the screen).
[0053] The sieved material can be mixed with maltose powder, and the mixing ratio can be 10-50wt% sieved material: 90-50wt% maltose. In Example 1, the sieved material is 20%. The mixture is stirred into a high-speed mixing granulator to obtain the second acidic powder.
[0054] Preparation of particles containing INF-α:
[0055] The second acidic powder was mixed with the active stock solution. The mixture was stirred into a high-speed mixer granulator for the steps of binder incorporation and granulation to obtain the first granules containing INF-α. Next, the first granules were dried at 30° C. for 7 minutes in a fluidized bed granulation dryer / coater and sieved with a 60-mesh screen (vibrating screen separator).
[0056] Then, it was mixed with the remaining portion of the first acidic powder in a drum mixer for 10 minutes. Magnesium stearate was added as an additional excipient to the drum mixer and mixed therein for 5 minutes.
[0057] The second granules containing INF-α were prepared using a high-speed mixer granulator.
[0058] In another alternative embodiment, after the addition of magnesium stearate, the mixture may be subjected to a tableting step.
[0059] In the following examples, various parameters of the process are changed and evaluated to find the optimal steps / parameters / conditions of the process.
[0060] Example 2: Evaluation of the protective effect of different factors on INF-α
[0061] Finding the optimal solution of the active stock solution for adjustment is very important for API potency. The optimal solution can maintain API potency throughout the manufacturing process. Table 1 shows the two-factor experimental design.
[0062] Table 1
[0063]
[0064] Figure 2 It shows that for the protective effects of different factors on INF-α, positive values indicate a protective effect on INF-α, while negative values indicate a destructive effect on INF-α. There is an interaction between the two factors, and positive values strengthen the protective effect of the interaction, while negative values weaken the protective effect.
[0065] result
[0066] When dissolved, all cytokines must be present in a buffer system with surfactants / stabilizers and must not contain stressing agents. Since most biomedical products are blood products, serum products, vaccines, cell therapy products, gene therapy products, biotechnology products, human or animal extract products, allergen products, and tissue engineering products. The aforementioned biomedical products are all sterile products. However, the orally disintegrating tablets containing cytokines manufactured by the process of the present invention are not sterile products. How to protect and maintain the efficacy and function of INF-α contained in the orally disintegrating tablet is the primary goal. The inventors not only constructed a more suitable manufacturing process, but also discovered the optimal parameters of the API. According to the inventors' research, see Figure 2 HS (human serum albumin), NaCl, pH adjustment, WFI (water for injection), and EDTA have protective effects. Relatively speaking, the higher the interferon concentration, the worse the protective effect; this is because the higher the interferon concentration, the lower the HS protective agent concentration. In addition, salts and HS are antagonistic to each other. When the concentrations of both increase, the protective effect weakens; and the interaction with other experimental factors will strengthen each other. Combining this discovery with the two processes, the biological solid dosage form will have a beneficial effect.
[0067] Example 3: Evaluation of Excipient Acidification Step
[0068] This example tests the preparation method of a pharmaceutical composition comprising IFN-α and maltose. First, 1 kg of maltose powder is acidified and granulated with 0.1% citric acid solution in a high shear mixer, and dried in a fluidized bed granulation dryer for 15 minutes to obtain an acidified powder. Next, 8.9 μg of API solution, 510 mg of sodium acetate, 2.76 g of NaCl, 450 mg of HSA, and 1.65 ml of HCl are mixed with sterile water or purified water to prepare 150 ml of active stock solution. Subsequently, 472.4 g of the acidic powder and the active stock solution are granulated and dried in a fluidized bed granulation dryer. Figure 3 The results show that the INF-α content in the powder obtained by secondary granulation was measured by ELISA, and the acidified group was compared with the non-acidified group. The acidified group showed a higher retention rate, indicating that this excipient acidification step can effectively protect the stability of IFN-α.
[0069] Example 4: Water ratio of acidified solution
[0070] This experiment tested the adjustment of the proportion of water in the acidified solution and evaluated the effect on the granulation step. 0.5 kg of maltose powder was tested with different volumes of coloring water. When the ratio of water to maltose was 6-8 g / 100 g, a more uniform particle distribution was observed. However, when the water content was too low (5 g / 100 g), coarse and fine particles of different shades of color were observed after granulation, indicating that the powder uniformity was poor. In addition, too high a water content would cause the maltose to dissolve and adhere to the container wall, forming large crystalline aggregates that are not conducive to yield.
[0071] Example 5: Granulation equipment for acidic powders
[0072] This example uses 0.5 kg maltose powder and 0.1% citric acid solution. The granulation equipment tested includes a high shear mixer (SMG group) and a fluidized bed granulation dryer (FBD group). The powder particle size was measured after granulation. It was observed that the FBD group showed a greater difference in particle size, showing a significant aggregation ratio. On the contrary, the SMG group showed a more uniform particle size distribution. Therefore, the granulation step of the powder form is preferably performed with a high shear mixer.
[0073] On the other hand, the drying step is preferably carried out in a fluidized bed granulation dryer, with the temperature set at 55-60°C and the drying time at 10-20 minutes. The water content analysis shows that it is about 1±0.5%. Similar results can be obtained with a vacuum pump, but it takes several hours; the use of a fluidized bed granulation dryer can reduce the time cost and the possibility of accidents during the production process.
[0074] Example 6: Processing of the first acidic powder
[0075] In this example, 1 kg of maltose powder and 0.1% citric acid solution (61 g) were acidified and granulated with a high shear mixer, and then dried with a fluidized bed granulation dryer for 15 minutes. The acidic powder was sieved with a 100 mesh screen, the sieved particles were mixed with the active stock solution, and granulated / dried with a fluidized bed granulation dryer to obtain a secondary granulated powder. Finally, the secondary granulated powder, acidic powder, and magnesium stearate were mixed in a weight ratio of 1:0.98-1:0-0.02 and tableted. The INF-α efficacy of the tablets was tested, and the results were as follows: Figure 4 As shown. For the orally disintegrating tablet containing INF-α, it is required that INF-α must be evenly distributed in each orally disintegrating tablet. The results of the efficacy test cannot directly reflect the content of INF-α. Figure 4 As shown, the coefficient of variation of the sieved group samples was less than 15%, indicating that adding a sieving step before secondary granulation can improve the uniformity of orally disintegrating tablets.
[0076] Example 7: Comparison of secondary granulation equipment
[0077] In this example, the secondary granulation equipment tested includes a high shear mixer and a fluidized bed granulation dryer. When the fluidized bed granulation dryer is used, the tablets are prepared according to the steps of Example 6. When the high shear mixer is used, the steps for preparing the orodisintegrating tablets are the same as those of Example 6, but the difference is that the sieved granules and the active stock solution are granulated with a high shear mixer, and then dried with FBD to obtain the second acidic powder. The results are shown in FIG. Figure 5 As shown, the differences between samples were less than 20%.
[0078] like Figure 5 As shown, compared with FBD, SMG equipment granulation can retain a higher proportion of INF-α attached to the acidic powder and a higher uniformity of orally disintegrating tablets.
[0079] Example 8: Orally disintegrating tablet thickness
[0080] In this example, the effect of orally disintegrating tablet thickness was evaluated. The tableting parameters were adjusted to increase the thickness from 3.6 mm to 4.0 mm, and the samples were tested for INF-α efficacy. Figure 6 The data show that increasing the thickness of the orally disintegrating tablets did not change the uniformity but provided better protection of INF-α potency.
[0081] The present invention is disclosed with reference to the above preferred embodiments and examples. It is understood that the embodiments are only illustrative and not intended to limit the present invention. Personnel with ordinary knowledge in the art may modify or combine the above embodiments without violating the spirit and scope of the present invention; therefore, all equivalent modifications or changes made without departing from the spirit and technical ideas disclosed by the present invention should still be covered by the claims of the present invention.
Claims
1. A process for manufacturing an orally disintegrating tablet (ODT) comprising a cytokine as an active pharmaceutical ingredient, characterized in that: include: Acidifying excipients; subjecting the acidified excipient to a first granulation step to obtain an acidic powder; and The acidic powder is mixed with the cytokine to perform a second granulation step to obtain granules containing the cytokine.
2. The process according to claim 1, characterized in that The cytokine is selected from one or more of the following groups: chemokine, interferon, interleukin, lymphokine, and tumor necrosis factor.
3. The process according to claim 1, characterized in that: The excipient is selected from one or more of the following groups: sugar, carbohydrate alcohol, cellulose, polysaccharide, stearic acid, magnesium stearate, calcium stearate, polyethylene glycol, sodium lauryl sulfate, glycerol, anhydrous dicalcium phosphate, magnesium aluminosilicate, and silicon oxide.
4. The process according to claim 1, characterized in that: The excipient was acidified via the following steps: providing an acid solution comprising an acid and water, and mixing the excipient with the acid solution, The obtained solution comprising the excipient, acid and water has a pH value of 3 to 10.
5. The process according to claim 1, characterized in that: The cytokine is contained in a solution, the solution includes a solvent and an additive, and the solution including the cytokine, the solvent and the additive has a pH value of 3-10.
6. A process for manufacturing an orally disintegrating tablet (ODT) comprising a cytokine as an active pharmaceutical ingredient, characterized in that: include: acidifying the first excipient; subjecting the acidified first excipient to a first granulation step to obtain a first acidic powder; sieving and granulating the first acidic powder to obtain a second acidic powder; The second acidic powder is mixed with the cytokine to perform a second granulation step to obtain first granules containing the cytokine.
7. The process according to claim 6, characterized in that The method further comprises: tableting the first granules to form an orally disintegrating tablet; or, mixing the first granules with the first excipient and / or additive, and tableting the mixture to form an orally disintegrating tablet.
8. The process according to claim 6, characterized in that: The first excipient is acidified via the following steps: providing an acid solution comprising an acid and water, and mixing the excipient with the acid solution, The obtained solution comprising the excipient, acid and water has a pH value of 3 to 10.
9. The process according to claim 6, characterized in that: The cytokines are selected from one or more of the following groups: chemokines, interferons, interleukins, lymphokines and tumor necrosis factors; and the first excipient, the second excipient or the additive is selected from one or more of the following groups: sugars, glycols, cellulose, polysaccharides, stearic acid, magnesium stearate, calcium stearate, polyethylene glycol, sodium lauryl sulfate, glycerol, anhydrous dicalcium phosphate, magnesium aluminosilicate, and silicon oxide.
10. An orally disintegrating tablet (ODT) comprising a cytokine as an active pharmaceutical ingredient, characterized in that: It is manufactured by the process of claim 1 or claim 6.
